We serve Chemical Name:4-(Benzylamino)-3-nitrobenzoic acid CAS:68502-37-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(Benzylamino)-3-nitrobenzoic acid
CAS.NO:68502-37-4
Synonyms:4-benzylamino-3-nitrobenzoic acid
Molecular Formula:C14H12N2O4
Molecular Weight:272.25600
HS Code:2922499990
Physical and Chemical Properties:
Melting point:N/A
Boiling point:475.3ºC at 760 mmHg
Density:1.403g/cm3
Index of Refraction:1.686
PSA:95.15000
Exact Mass:272.08000
LogP:3.50130
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-benzylamino-3-nitrobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-benzylamino-3-nitrobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-benzylamino-3-nitrobenzoic acid Use and application,4-benzylamino-3-nitrobenzoic acid technical grade,usp/ep/jp grade.
Related News: The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 4-(Benzylamino)-3-nitrobenzoic acid manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. 4-(Benzylamino)-3-nitrobenzoic acid supplier In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. 4-(Benzylamino)-3-nitrobenzoic acid vendor The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 4-(Benzylamino)-3-nitrobenzoic acid factory Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report.
